Celcuity (CELC) Stock: Buy, Sell, or Hold?
CELC - Celcuity Inc. Common Stock
$75.13
-4.39 (-5.52%)
▼
5d:
-5.34%
30d:
-18.32%
90d:
-30.4%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CELC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CELC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CELC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CELC is currently trading at $75.13, which is considered oversold relative to its 30-day fair value range of $80.66 to $92.60. From a valuation perspective, the stock is trading at a discount (Forward PE: -939.1) compared to its historical average (125.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CELC is in a strong downtrend. The price is currently testing key support at $75.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $159.64 (+112.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CELC is in a strong downtrend. The price is currently testing key support at $75.00. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $159.64 (+112.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$80.66 -
$92.60
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding CELC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 112.5% below Wall St target ($159.64)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$80.66 -
$92.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$75.00
Resistance Level
$88.68
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-939.12
Wall Street Target
$159.64
(+112.5%)
PE vs Historical
-939.1 vs 125.4
CHEAP
Share & Embed Analysis
Last updated: October 01, 2026 10:25 PM ET
Data refreshes hourly during market hours. Next update: 11:25 PM
Data refreshes hourly during market hours. Next update: 11:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
Advanced CELC Option Strategies
Professional options setups generated by AI based on today's CELC price and gamma walls.
